** Shares of Lexicon Pharmaceuticals LXRX.O drop 11.75% to 63 cents before the bell
** Late on Friday, U.S. FDA declined to approve the biopharma company's add-on drug for type 1 diabetes and chronic kidney disease
** Company had previously disclosed its strategic decision to discontinue launch preparations for the drug
** Company had said in November it would reduce its workforce by about 60%, after the U.S. FDA noted deficiencies in its application seeking approval for its diabetes drug
** LXRX to focus on development of other products
** A panel of advisers to the FDA had voted against recommending the drug, sotagliflozin, as an add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease
** Up to last close, stock down ~53% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。